Search Results

InspireMD and Jacobs Institute to Conduct EFS of CGuard EPS in Acute Stroke Patients With Tandem Lesions

November 27, 2023—InspireMD, Inc., developer of the CGuard embolic prevention system (EPS) for the prevention of stroke, announced that the company has entered into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo, and Adnan Siddiqui, MD, Vice-Chairman and Professor of Neurosurgery, to execute an early feasibility study (EFS) evaluating the safety and feasibility of the CGuard EPS carotid stent to treat severe carotid stenosis or occlusion in conjunction with thrombectomy in patients presenting with acute ischemic stroke and tandem lesions.

AVS Partners With Jacobs Institute to Expedite Trials for Coronary and Carotid Indications of Pulse IVL System

August 20, 2024—Amplitude Vascular Systems (AVS), which is focused on the treatment of severely calcified arterial disease with its Pulse platform, announced it has entered into a strategic agreement with the Jacobs Institute, a nonprofit medical device innovation center in Buffalo, New York, led by Adnan Siddiqui, MD.

Nanoflex Robotics System for Vascular Interventions Introduced in North America at Jacobs Institute

March 7, 2024—Nanoflex Robotics AG, which is headquartered in Switzerland, announced the introduction in North America of its remote-ready robotics system for vascular interventions.

Serenity’s River Venous Sinus Stent Studied to Treat Idiopathic Intracranial Hypertension

February 20, 2025—Serenity Medical announced the publication of 1-year results of the RIVER study by Athos Patsalides, MD, et al in Journal of NeuroInterventional Surgery.

Blockade Medical Announces FDA Clearance and CE Mark Approval of Additions to the Barricade Coil System

March 4, 2014—Blockade Medical LLC (Irvine, CA), a developer of catheter-based therapeutic devices for the treatment of cerebral aneurysms, announced two additions to the company’s Barricade coil system: an enhanced framing coil and a complex finishing coil.

FDA Approves IDE for Pulsar Vascular's PulseRider Aneurysm Neck Reconstruction Device

June 10, 2014—Pulsar Vascular announced that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for the PulseRider, the company’s minimally invasive aneurysm neck reconstruction device.

Anaconda’s ANA Funnel Catheter to Be Evaluated in ATHENA Study

July 17, 2024—Anaconda Biomed SL, a developer of next-generation thrombectomy systems, announced that it received conditional investigational device exemption approval from the FDA to begin the ATHENA study of its ANA5 advanced neurovascular access funnel catheter, which is designed to facilitate flow arrest during clot retrieval.

Rapid Medical’s Comaneci Embolization-Assist Device Compared With Stent- and Balloon-Assisted Coiling Devices

July 19, 2023—Rapid Medical, an Israel-based developer of neurovascular devices, announced new clinical data showing significant advantages of the company’s Comaneci embolization-assist device versus established techniques of stent-assisted coiling (SAC) and balloon-assisted coiling (BAC) techniques to treat ruptured wide-neck intracranial aneurysms.

Canon Medical Introduces 12- X 16-Inch High-Definition Detector

November 23, 2021—Canon Medical Systems Corporation announced the introduction of a new size for its high-definition flat-panel detector: the 12- X 16-inch high-definition detector.

Serenity Medical Gains FDA Humanitarian Device Exemption for River Cerebral Venous Stent

April 1, 2026—Serenity Medical announced that the United States FDA has granted Humanitarian Device Exemption (HDE) approval for the River stent for the treatment of severe idiopathic intracranial hypertension (IIH) in adult patients who have failed medical therapy.

AVS Raises Financing to Support Pulse IVL System Launch in the United States

January 28, 2025—Amplitude Vascular Systems (AVS), developer of the Pulse intravascular lithotripsy (PIVL) platform for the treatment of severely calcified arterial disease, announced that it has completed a Series B round of financing of $36 million.

Synchron’s COMMAND Trial of Brain-Computer Interface Enrolls Patients at the Gates Vascular Institute

March 20, 2023—Synchron, an endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, announced that the COMMAND trial is commencing enrollment at its third approved site, the Gates Vascular Institute, which is a Kaleida Health facility and a teaching affiliate of the Jacobs School of Medicine and Biomedical Sciences of the University at Buffalo in Buffalo, New York.